Standout Papers

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer 2020 2026 2022 2024445
  1. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (2020)
    Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

The balance of STING signaling orchestrates immunity in cancer
2024 Standout
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
3 intermediate papers

Works of Christopher Gresty being referenced

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
2020 Standout
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Christopher Gresty 680 417 72 332 22 874
Alexandra S. Zimmer 786 325 74 350 24 1.1k
Lindsey Rolfe 606 194 99 367 30 837
Matin Sheriff 525 183 69 351 32 968
Beth A. Hellerstedt 551 312 95 310 32 992
Corrine Zarwan 671 197 70 316 27 1.1k
Baruch Klein 350 258 182 190 28 745
Weixiu Luo 646 131 98 256 17 993
Éric Charpentier 638 159 102 392 22 1.0k
Luan Nguyen 476 183 117 409 14 857
Natalia Bednarz‐Knoll 470 200 35 274 28 769

All Works

Loading papers...

Rankless by CCL
2026